Seres pro­motes CFO Er­ic Shaff to suc­ceed Pomer­antz as CEO; Ex­elix­is' Cabome­tyx bags US ap­proval for liv­er can­cer

→ Months af­ter poach­ing As­traZeneca vet Kevin Hor­gan to serve as CMO at mi­cro­bio­me drug de­vel­op­er Seres, the Cam­bridge, MA-based com­pa­ny has el­e­vat­ed CFO Er­ic Shaff to the po­si­tion of CEO, to suc­ceed Roger Pomer­antz, who will re­main board chair­man. Shaff, who will con­tin­ue to serve as Seres’ prin­ci­pal fi­nan­cial of­fi­cer on an in­ter­im ba­sis, joined the com­pa­ny in 2014 as CFO and was giv­en the ad­di­tion­al po­si­tion of COO in ear­ly last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER